Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A study found low rates of cancer recurrence, progression, or new malignancy among patients with psoriasis and prior neoplasia receiving interleukin-23 (IL-23) inhibitors. Researchers conducted a ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

1 One case of infusion reaction and one case of pruritus, both Grade 1 and resolved without medication. 2 One case of asymptomatic increased lipase, isolated to Day 43 post-dose (Grade 3); One case of ...

Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel ...